Abstract
There are few reports about the occurrence of hepatic VOD after BMT for severe aplastic anemia (SAA). We prospectively studied 17 patients with SAA after allogeneic BMT for the occurrence and severity of VOD. Plasma levels of protein C, protein S, antithrombin III, vWF, t-PA and PAI-1 were determined before preparative chemotherapy, on the day of marrow infusion, and on days 7, 14 and 21. VOD occurred in seven patients (41.2%) at a median of day 1 (range, day −2 to 15). Five had mild, and two moderate VOD. Platelet transfusion requirements were higher in the patients with VOD. The plasma levels of natural anticoagulants such as protein C, free protein S and antithrombin III decreased significantly on day 0 from the baseline levels. Plasma levels of t-PA, PAI-1 and vWF increased significantly in the early post-transplant period compared to the baseline levels. The mean plasma levels of t-PA on day 7 (P = 0.016) and PAI-1 on days 0 and 7 (P = 0.016, 0.032) were higher in the patients with VOD. In summary, we observed hypercoagulability and a high incidence of VOD after allogeneic BMT for SAA. Levels of t-PA and PAI-1 were significantly higher in the patients with VOD after BMT. Bone Marrow Transplantation (2000) 26, 657–662.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bearman SI . The syndrome of hepatic veno-occlusive disease after marrow transplantation Blood 1995 85: 3005–3020
McDonald GB, Hinds MS, Fisher LD et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients Ann Intern Med 1993 118: 255–267
Locasciulli A, Bacigalupo A, Alberti A et al. Predictability before transplant of hepatic complications following allogeneic bone marrow transplantation Transplantation 1989 48: 68–72
Witherspoon RP, Storb R, Shulman H et al. Marrow transplantation in hepatitis-associated SAA Am J Hematol 1984 17: 269–278
Zanis-Neto J, Ribeiro RC, Medeiros C et al. Bone marrow transplantation for patients with Fanconi anemia: a study of 24 cases from a single institute Bone Marrow Transplant 1995 15: 293–298
DeLeve LD . Cellular target of cyclophosphamide toxicity in the murine liver: role of glutathione and site of metabolic activation Hepatology 1996 24: 830–837
Goldberg JW, Lidsky MD . Cyclophosphamide-associated hepatotoxicity South Med J 1985 78: 222–223
Clelland BD, Pokorny CS . Cyclophosphamide related hepatotoxicity Aust N Z J Med 1993 23: 408
Modzelewski JR, Daeschner C, Joshi VV et al. Veno-occlusive disease of the liver induced by low dose cyclophosphamide Mod Pathol 1994 7: 967–972
Teicher BA, Crawford JM, Holden SA et al. Glutathione monoethyl ester can selectively protect liver from high dose BCNU or cyclophosphamide Cancer 1988 62: 1275–1281
Shulman HM, Hinterberger W . Hepatic veno-occlusive disease – liver toxicity syndrome after bone marrow transplantation Bone Marrow Transplant 1992 10: 197–214
Rozman C, Carreras E, Qian C et al. Risk factors for hepatic veno-occlusive disease following HLA-identical sibling bone marrow transplants for leukemia Bone Marrow Transplant 1996 17: 75–80
Bunin N, Leahey A, Dunn S . Related donor liver transplant for veno-occlusive disease following T-depleted unrelated donor bone marrow transplantation Transplantation 1996 61: 664–666
Rocha V, Devergie A, Socie G et al. Unusual complications after bone marrow transplantation for dyskeratosis congenita Br J Haematol 1998 103: 243–248
Shulman HM, McDonald GB, Matthews D et al. An analysis of hepatic venocclusive disease and centrilobular hepatic degeneration following bone marrow transplantation Gastroenterology 1980 79: 1178–1191
Slattery JT, Kalhorn TF, McDonald GB et al. Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients J Clin Oncol 1996 14: 1484–1494
Baglin TP . Veno-occlusive disease of the liver complicating bone marrow transplantation Bone Marrow Transplant 1994 13: 1–4
Rio B, Andreu G, Nicod A et al. Thrombocytopenia in venocclusive disease after bone marrow transplantation or chemotherapy Blood 1986 67: 1773–1776
Harper PL, Jarvis J, Jennings I et al. Changes in the natural anticoagulants following bone marrow transplantation Bone Marrow Transplant 1990 5: 39–42
Gordon B, Haire W, Kessinger A et al. High frequency of antithrombin 3 and protein C deficiency following autologous bone marrow transplantation for lymphoma Bone Marrow Transplant 1991 8: 497–502
Collins PW, Gutteridge CN, O'Driscoll A et al. von Willebrand factor as a marker of endothelial cell activation following BMT Bone Marrow Transplant 1992 10: 499–506
Catani L, Gugliotta L, Mattioli Belmonte M et al. Hypercoagulability in patients undergoing autologous or allogeneic BMT for hematological malignancies Bone Marrow Transplant 1993 12: 253–259
Salat C, Holler E, Reinhardt B et al. Parameters of the fibrinolytic system in patients undergoing BMT: elevation of PAI-1 in veno-occlusive disease Bone Marrow Transplant 1994 14: 747–750
Lee JH, Lee KH, Kim S et al. Relevance of proteins C and S, antithrombin III, von Willebrand factor, and factor VIII for the development of hepatic veno-occlusive disease in patients undergoing allogeneic bone marrow transplantation: a prospective study Bone Marrow Transplant 1998 22: 883–888
Salat C, Holler E, Kolb HJ et al. Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation Blood 1997 89: 2184–2188
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lee, JH., Lee, KH., Choi, SJ. et al. Veno-occlusive disease of the liver after allogeneic bone marrow transplantation for severe aplastic anemia. Bone Marrow Transplant 26, 657–662 (2000). https://doi.org/10.1038/sj.bmt.1702583
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1702583
Keywords
This article is cited by
-
Preclinical validation and treatment of volumetric modulated arc therapy based total bone marrow irradiation in Halcyon™ ring gantry linear accelerator
Radiation Oncology (2022)
-
Antineoplastic agent busulfan regulates a network of genes related to coagulation and fibrinolysis
European Journal of Clinical Pharmacology (2012)
-
A randomized comparison of cyclophosphamide vs. reduced dose cyclophosphamide plus fludarabine for allogeneic hematopoietic cell transplantation in patients with aplastic anemia and hypoplastic myelodysplastic syndrome
Annals of Hematology (2012)
-
Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation
Annals of Hematology (2005)
-
Monthly prospective analysis of hematopoietic chimerism after allogeneic hematopoietic cell transplantation
Bone Marrow Transplantation (2003)